Dr. Klaus Biemel has taken over the role of the Managing Director of Pharmacelsus GmbH (Member of GBA Group Pharma). Dr. Biemel has proven his management skills as an executive (COO) of Pharmacelsus from 2007 to 2018, and brings almost 20 years of experience in the field of ADMET, DMPK and bioanalysis.

He became an expert in the assessment and development of small molecules and therapeutic peptides entities, including the overseeing and directing of preclinical profiling and development operations.

He is food chemists by training and obtained his PhD at the University of Hohenheim for his research in the field of the formation of advanced glycation end products (AGEs) which are known to contribute to various pathologies associated with the general aging process and long term complications of diabetes.

"It is my vision for Pharmacelsus to position it as an innovative and trusted key player in preclinical ADME/Tox field and GCLP bioanalysis support."